Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the grant of non-qualified stock options totaling 250 shares to a new employee on September 30, 2020. This grant was made under Xeris’ Inducement Equity Plan, designed for individuals not previously employed by the company. The options will vest over four years, with structured timelines based on continued employment. Xeris aims to simplify therapy administration through innovative, ready-to-use formulations, enhancing patient experience and healthcare system efficiency.